SESN - Sesen Bio GAAP EPS of -$0.04 beats by $0.07
- Sesen Bio press release ( NASDAQ: SESN ): Q4 GAAP EPS of -$0.04 beats by $0.07 .
- Cash, cash equivalents and marketable securities were $166.9 million as of December 31, 2022, compared to cash and cash equivalents of $162.6 million as of December 31, 2021.
-
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders
Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors
- Shares -1.17% PM.
For further details see:
Sesen Bio GAAP EPS of -$0.04 beats by $0.07